Abstract
This letter aims to address the main discussion points raised regarding our previous publication. We acknowledge the importance of methodological consistency for reproducibility, although its influence may be limited within the context of our study design. We also concur with the suggestion to include immunotherapy, such as immune checkpoint inhibitors, in future analyses. Due to the limited number of eligible studies, these were not incorporated in the present work. Furthermore, we recognize the significance of standardized toxicity reporting and pharmacovigilance in integrative oncology research. While detailed safety monitoring was beyond the scope of our study, we plan to integrate standardized safety assessment frameworks in subsequent trials.
